Adamis Pharmaceuticals Corp - FORM 10-K - EX-32.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - March 15, 2018

Attached files

file filename
EX-32.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex32-1.htm
EX-31.2 - CERTIFICATION BY CHIEF FINANCIAL OFFICER - Adamis Pharmaceuticals Corpex31-2.htm
EX-31.1 - CERTIFICATION BY CHIEF EXECUTIVE OFFICER - Adamis Pharmaceuticals Corpex31-1.htm
EX-23.1 - AUDITOR'S CONSENT - Adamis Pharmaceuticals Corpex23-1.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Adamis Pharmaceuticals Corpex21-1.htm
EX-10.79 - MARCH 2018 AMENDED AND RESTATED LINE OF CREDIT PROMISSORY NOTE - Adamis Pharmaceuticals Corpex10-79.htm
EX-10.78 - MARCH 2018 AMENDMENT TO LOAN AND SECURITY AGREEMENT - Adamis Pharmaceuticals Corpex10-78.htm
10-K - ANNUAL REPORT - Adamis Pharmaceuticals Corpadmp_10k-123117.htm
 

ADAMIS PHARMACEUTICALS CORPORATION 10-K

 

 

Exhibit 32.2

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

 

The undersigned, Robert O. Hopkins, as Vice President, Finance and Chief Financial Officer of Adamis Pharmaceuticals, Corporation (the “Company”), pursuant to 18 U.S.C.  1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:

 

   (1) the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
   
   (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

   
  /s/ ROBERT O. HOPKINS
  Robert O. Hopkins
  Vice President and Chief Financial Officer

 

Dated: March 15, 2018 

 

This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

 

 

 

Stock widget

Investing forum

Adamis Pharmaceuticals Corp Reports